| Comprehensive genomic profiles of small cell lung cancer J George, JS Lim, SJ Jang, Y Cun, L Ozretić, G Kong, F Leenders, X Lu, ... Nature 524 (7563), 47-53, 2015 | 1955 | 2015 |
| p53-deficient cells rely on ATM-and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage HC Reinhardt, AS Aslanian, JA Lees, MB Yaffe Cancer cell 11 (2), 175-189, 2007 | 726 | 2007 |
| Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2 HC Reinhardt, MB Yaffe Current opinion in cell biology 21 (2), 245-255, 2009 | 624 | 2009 |
| The p53 network: cellular and systemic DNA damage responses in aging and cancer HC Reinhardt, B Schumacher Trends in Genetics 28 (3), 128-136, 2012 | 549 | 2012 |
| The combined status of ATM and p53 link tumor development with therapeutic response H Jiang, HC Reinhardt, J Bartkova, J Tommiska, C Blomqvist, ... Genes & development 23 (16), 1895-1909, 2009 | 347 | 2009 |
| Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels TB Huber, B Schermer, RU Müller, M Höhne, M Bartram, A Calixto, ... Proceedings of the National Academy of Sciences 103 (46), 17079-17086, 2006 | 344 | 2006 |
| Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches F Dietlein, L Thelen, HC Reinhardt Trends in genetics 30 (8), 326-339, 2014 | 305 | 2014 |
| A Mitotic Phosphorylation Feedback Network Connects Cdk1, Plk1, 53BP1, and Chk2 to Inactivate the G2/M DNA Damage Checkpoint MATM van Vugt, AK Gardino, R Linding, GJ Ostheimer, HC Reinhardt, ... PLoS biology 8 (1), e1000287, 2010 | 287 | 2010 |
| Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response HC Reinhardt, MB Yaffe Nature reviews Molecular cell biology 14 (9), 563-580, 2013 | 282 | 2013 |
| 14-3-3σ controls mitotic translation to facilitate cytokinesis EW Wilker, MATM Van Vugt, SC Artim, PH Huang, CP Petersen, ... Nature 446 (7133), 329-332, 2007 | 282 | 2007 |
| DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization HC Reinhardt, P Hasskamp, I Schmedding, S Morandell, MATM van Vugt, ... Molecular cell 40 (1), 34-49, 2010 | 271 | 2010 |
| Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia CD Herling, N Abedpour, J Weiss, A Schmitt, RD Jachimowicz, O Merkel, ... Nature communications 9 (1), 727, 2018 | 203 | 2018 |
| NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway S Habbig, MP Bartram, RU Müller, R Schwarz, N Andriopoulos, S Chen, ... Journal of Cell Biology 193 (4), 633-642, 2011 | 172 | 2011 |
| Expression of functional CCR and CXCR chemokine receptors in podocytes TB Huber, HC Reinhardt, M Exner, JA Burger, D Kerjaschki, MA Saleem, ... The Journal of Immunology 168 (12), 6244-6252, 2002 | 159 | 2002 |
| Exploiting synthetic lethal interactions for targeted cancer therapy HC Reinhardt, H Jiang, MT Hemann, MB Yaffe Cell cycle 8 (19), 3112-3119, 2009 | 147 | 2009 |
| Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy CD Herling, M Klaumünzer, CK Rocha, J Altmüller, H Thiele, J Bahlo, ... Blood, The Journal of the American Society of Hematology 128 (3), 395-404, 2016 | 146 | 2016 |
| KIBRA modulates directional migration of podocytes K Duning, EM Schurek, M Schlu, M Bayer, HC Reinhardt, A Schwab, ... Journal of the American Society of Nephrology 19 (10), 1891-1903, 2008 | 135 | 2008 |
| Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer L Meder, P Schuldt, M Thelen, A Schmitt, F Dietlein, S Klein, S Borchmann, ... Cancer research 78 (15), 4270-4281, 2018 | 134 | 2018 |
| A synergistic interaction between Chk1-and MK2 inhibitors in KRAS-mutant cancer F Dietlein, B Kalb, M Jokic, EM Noll, A Strong, L Tharun, L Ozretić, ... Cell 162 (1), 146-159, 2015 | 133 | 2015 |
| Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors J Fassunke, F Müller, M Keul, S Michels, MA Dammert, A Schmitt, ... Nature communications 9 (1), 4655, 2018 | 129 | 2018 |
Thomas BenzingProfessor of Medicine, University of CologneVerified email at uk-koeln.de
